Daiichi Sankyo Company Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Sunao Manabe

Chief Executive Officer (CEO)

JP¥401.0m

Compensación total

Porcentaje del salario del CEO	26.9%
Permanencia del CEO	5yrs
Participación del CEO	0.008%
Permanencia media de la dirección	3.2yrs
Promedio de permanencia en la Junta Directiva	4yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why Daiichi Sankyo Company (TSE:4568) Has Caught The Eye Of Investors

May 22

Statutory Profit Doesn't Reflect How Good Daiichi Sankyo Company's (TSE:4568) Earnings Are

May 02

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Apr 27

Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year

Mar 11

Daiichi Sankyo Company (TSE:4568) Will Pay A Larger Dividend Than Last Year At ¥30.00

Feb 26

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Sunao Manabe en comparación con los beneficios de Daiichi Sankyo Company?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	JP¥201b
Dec 31 2023	n/a	n/a	JP¥186b
Sep 30 2023	n/a	n/a	JP¥148b
Jun 30 2023	n/a	n/a	JP¥147b
Mar 31 2023	JP¥401m	JP¥108m	JP¥109b
Dec 31 2022	n/a	n/a	JP¥59b
Sep 30 2022	n/a	n/a	JP¥63b
Jun 30 2022	n/a	n/a	JP¥51b
Mar 31 2022	JP¥341m	JP¥108m	JP¥67b
Dec 31 2021	n/a	n/a	JP¥94b
Sep 30 2021	n/a	n/a	JP¥87b
Jun 30 2021	n/a	n/a	JP¥79b
Mar 31 2021	JP¥170m	JP¥99m	JP¥76b
Dec 31 2020	n/a	n/a	JP¥71b
Sep 30 2020	n/a	n/a	JP¥116b
Jun 30 2020	n/a	n/a	JP¥118b
Mar 31 2020	JP¥197m	JP¥97m	JP¥129b
Dec 31 2019	n/a	n/a	JP¥149b
Sep 30 2019	n/a	n/a	JP¥114b
Jun 30 2019	n/a	n/a	JP¥113b
Mar 31 2019	JP¥165m	JP¥90m	JP¥93b

Compensación vs. Mercado: La compensación total de Sunao($USD2.58M) está por encima de la media de empresas de tamaño similar en el mercado JP ($USD1.58M).

Compensación vs. Ingresos: La compensación de Sunao ha sido consistente con los resultados de la empresa en el último año.

CEO

Sunao Manabe (70 yo)

5yrs

Permanencia

JP¥401,000,000

Compensación

Mr. Sunao Manabe, D.V.M, Ph D., had been President of Daiichi Sankyo Company, Limited since April 1, 2017 until April 01, 2023 and serves as its Chief Executive Officer since June 17, 2019 and serves as it...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Sunao Manabe	Group CEO & Executive Chairperson	5yrs	JP¥401.00m	0.0080% ¥ 824.0m
Hiroyuki Okuzawa	President	1.2yrs	JP¥151.00m	0.0021% ¥ 216.6m
Shoji Hirashima	Senior Managing Executive Officer	5.2yrs	JP¥166.00m	0.0036% ¥ 374.2m
Koji Ogawa	Managing Executive Officer	7.2yrs	sin datos	sin datos
N/A Chiyu	General Manager of Finance & Accounting Department	no data	sin datos	sin datos
Hiroto Kashiwase	Managing Executive Officer & Head of Technology Division	no data	sin datos	sin datos
Naoto Tsukaguchi	Gen. Counsel	no data	sin datos	sin datos
Matt Allegrucci	Head of Global Compliance & Risk Management and Chief Compliance Officer	less than a year	sin datos	sin datos
Kentaro Asakura	Vice President of Corporate Communications Department	no data	sin datos	sin datos
Marielle Cohard-Radice	Global Head of Development	no data	sin datos	sin datos
Akio Sakurai	Corporate Officer	3.2yrs	sin datos	sin datos
Takashi Matsumoto	Managing Executive Officer	2.4yrs	sin datos	sin datos

3.2yrs

Permanencia media

63yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 4568 se considera experimentado (3.5 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Sunao Manabe	Group CEO & Executive Chairperson	10yrs	JP¥401.00m	0.0080% ¥ 824.0m
Hiroyuki Okuzawa	President	3yrs	JP¥151.00m	0.0021% ¥ 216.6m
Shoji Hirashima	Senior Managing Executive Officer	4yrs	JP¥166.00m	0.0036% ¥ 374.2m
Takashi Fukuoka	Senior Managing Exec. Officer	2yrs	sin datos	0.00073% ¥ 75.7m
Kazuaki Kama	Independent Outside Chairperson	5yrs	sin datos	0.00021% ¥ 21.8m
Takaaki Nishii	Independent Outside Director	less than a year	sin datos	0.000050% ¥ 5.2m
Masahiko Ohtsuki	Director	4yrs	JP¥153.00m	0.0031% ¥ 325.4m
Sawako Nohara	Independent Outside Director	5yrs	sin datos	0.000050% ¥ 5.2m
Miyuki Arai	Member of Audit & Supervisory Board	less than a year	sin datos	0.0010% ¥ 108.8m
Kenji Sato	Chairman of Audit & Supervisory Board	5yrs	sin datos	0.0013% ¥ 130.6m
Yukiko Imazu	Outside Audit & Supervisory Board Member	6yrs	sin datos	sin datos
Yasuhiro Komatsu	Independent Outside Director	2yrs	sin datos	sin datos

4.0yrs

Permanencia media

64yo

Promedio de edad

Junta con experiencia: La junta directiva de 4568 se considera experimentada (3.8 años de antigüedad promedio).

Daiichi Sankyo Company Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 17, 2024

Recent updates

Daiichi Sankyo and AstraZeneca PLC Provides Positive Results from the DESTINY-Breast06 Phase 3 Trial

Daiichi Sankyo and AstraZeneca PLC Provides an update on TROPION-Lung01 Phase 3 Trial

Here's Why Daiichi Sankyo Company (TSE:4568) Has Caught The Eye Of Investors

Statutory Profit Doesn't Reflect How Good Daiichi Sankyo Company's (TSE:4568) Earnings Are

Investor sentiment improves as stock rises 15%

AstraZeneca PLC and Daiichi Sankyo Announces ENHERTU (Fam-Trastuzumab Deruxtecan-Nxki) Improved PFS in HER2-Low and Ultralow

Now 27% overvalued after recent price rise

Daiichi Sankyo Company, Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited (TSE:4568) announces an Equity Buyback for 55,000,000 shares, representing 2.87% for ¥200,000 million.

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Daiichi Sankyo Company, Limited, Annual General Meeting, Jun 17, 2024

Upcoming dividend of JP¥30.00 per share

Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year

The European Medicines Agency Validates Two Marketing Authorization Applications for Daiichi Sankyo and AstraZeneca

Daiichi Sankyo Company, Limited to Report Fiscal Year 2024 Results on Apr 25, 2024

Consensus EPS estimates increase by 10%

Daiichi Sankyo Company (TSE:4568) Will Pay A Larger Dividend Than Last Year At ¥30.00

AstraZeneca and Daiichi Sankyo's Biologics License Application for Datopotamab Deruxtecan Accepted in the US

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited Provides Consolidated Earnings Guidance for the Year Ending March 31, 2024

Daiichi Sankyo Company, Limited Revises Dividend Guidance for the Year Ending March 31, 2024

Daiichi Sankyo and AstraZeneca Announces Two Phase 3 Trials of Datopotamab

Daiichi Sankyo Company, Limited to Report Q3, 2024 Results on Jan 31, 2024

Daiichi Sankyo Company, Limited Appeals Amended Texas Court Judgement in Patent Dispute with Seagen Inc

IHH Healthcare Berhad Announces Update on Claim Before the Tokyo District Court in Japan by NTK Against Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited's VANFLYTA (quizartinib) Approves in the EU as the First FLT3 Inhibitor Specifically for Patients with Newly Diagnosed FLT3-ITD Positive AML

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Astrazeneca and Daiichi Sankyo Announces Positive Results from the Pivotal Tropion-Breast01 Phase Iii Trial

Daiichi Sankyo and Astrazeneca’S Enhertu Demonstrated Clinically Meaningful Survival Across Multiple Her2 Expressing Advanced Solid Tumors in Destiny-Pantumor02 Phase 2 Trial

Daiichi Sankyo and Astrazeneca Announce Datopotamab Deruxtecan Plus Durvalumab Demonstrated Robust and Durable Tumor Responses in First-Line Treatment of Patients with Metastatic Triple Negative Breast Cancer in BEGONIA Phase 1b/2 Trial

Daiichi Sankyo and AstraZeneca Announce Datopotamab Deruxtecan Demonstrated Statistically Significant and Clinically Meaningful Progression-Free Survival Benefit in Patients with HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial

Upcoming dividend of JP¥17.00 per share at 0.9% yield

European Union Recommends ENHERTU for Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer

Daiichi Sankyo Company, Limited and AstraZeneca PLC Announce Datopotamab Deruxtecan Plus Durvalumab Showed Promising Clinical Activity in the First-Line Advanced Non-Small Cell Lung Cancer Setting in TROPION-Lung04 Phase 1b Trial

Daiichi Sankyo Announces First Patient Dosed in a First-In-Human Phase 1/2 Trial Evaluating DS-3939 in Patients with Several Types of Advanced Solid Cancers

Daiichi Sankyo Company, Limited's ENHERTU Receives Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers

Daiichi Sankyo Company, Limited to Report Q2, 2024 Results on Oct 31, 2023

Daiichi Sankyo Company, Limited Announces Vanflyta® Now Available in U.S. for Patients with Newly Diagnosed FLT3-ITD Positive AML

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Daiichi Sankyo Company, Limited and AstraZeneca PLC Reports ENHERTU Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad